Literature DB >> 17460385

Alterations in placental growth factor levels before and after the onset of preeclampsia are more pronounced in women with early onset severe preeclampsia.

Akihide Ohkuchi1, Chikako Hirashima, Shigeki Matsubara, Hirotada Suzuki, Kayo Takahashi, Fujimi Arai, Takashi Watanabe, Kazuomi Kario, Mitsuaki Suzuki.   

Abstract

It has been established that the serum placental growth factor (PlGF) decreases and the soluble fms-like tyrosine kinase-1 (sFlt-1) increases in women with preeclampsia. However, there have been no studies on the relation between preeclampsia onset time and the changes in PlGF and sFlt-1. Furthermore, the PlGF and sFlt-1 levels have not been evaluated using their reference values specific to each gestational age. In this study we reevaluated the serum PlGF and sFlt-1 levels before and after the clinical manifestation of early and late onset severe preeclampsia using the new reference values developed in our recent longitudinal study. Blood specimens were obtained immediately after the clinical manifestation of severe preeclampsia in 34 referred women, and both before and after the clinical manifestation in 8 women receiving a routine checkup at our institute. Both women with early and those with late preeclampsia showed decreased PlGF and increased sFlt-1 levels compared to normotensive controls at 28 and 37 weeks (n=68). However, those with early onset preeclampsia had a higher incidence of low PlGF (<5th percentile on the reference values) and high sFlt-1 (>or=95th percentile) than those with late onset (low PlGF: 93% vs. 55%; high sFlt-1: 100% vs. 60%). log10PlGF (r=0.574, p<0.001) and log10(sFlt-1/PlGF) (r=-0.556, p<0.001) were correlated with the week of onset of preeclampsia. Before the onset of preeclampsia, the incidence rate of low PlGF in the women with early onset preeclampsia was 100% (5/5), whereas that in the women with late onset preeclampsia was 0% (0/2) (p=0.048). Therefore, alterations in the PlGF levels both before and after the onset of preeclampsia may be more pronounced in women with early onset than those with late onset severe preeclampsia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17460385     DOI: 10.1291/hypres.30.151

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  23 in total

1.  An imbalance between angiogenic and anti-angiogenic factors precedes fetal death in a subset of patients: results of a longitudinal study.

Authors:  Roberto Romero; Tinnakorn Chaiworapongsa; Offer Erez; Adi L Tarca; Maria Teresa Gervasi; Juan Pedro Kusanovic; Pooja Mittal; Giovanna Ogge; Edi Vaisbuch; Shali Mazaki-Tovi; Zhong Dong; Sun Kwon Kim; Lami Yeo; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2010-05-12

2.  Low placental growth factor across pregnancy identifies a subset of women with preterm preeclampsia: type 1 versus type 2 preeclampsia?

Authors:  Robert W Powers; James M Roberts; Daniel A Plymire; Dominick Pucci; Saul A Datwyler; Don M Laird; David C Sogin; Arun Jeyabalan; Carl A Hubel; Robin E Gandley
Journal:  Hypertension       Date:  2012-05-29       Impact factor: 10.190

3.  Clinical usefulness of serum levels of soluble fms-like tyrosine kinase 1/placental growth factor ratio to rule out preeclampsia in women with new-onset lupus nephritis during pregnancy.

Authors:  Chikako Hirashima; Manabu Ogoyama; Miyuki Abe; Satoru Shiraishi; Taro Sugase; Toshiro Niki; Shigeki Matsubara; Akihide Ohkuchi
Journal:  CEN Case Rep       Date:  2018-12-18

4.  Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia.

Authors:  Tinnakorn Chaiworapongsa; Roberto Romero; Zeynep Alpay Savasan; Juan Pedro Kusanovic; Giovanna Ogge; Eleazar Soto; Zhong Dong; Adi Tarca; Bhatti Gaurav; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2011-08-09

Review 5.  Anti-angiogenesis and Preeclampsia in 2016.

Authors:  Susanne Schrey-Petersen; Holger Stepan
Journal:  Curr Hypertens Rep       Date:  2017-01       Impact factor: 5.369

6.  Increased antiangiogenetic factors in severe proteinuria without hypertension in pregnancy: is kidney biopsy necessary?

Authors:  Takako Ohmaru; Akihide Ohkuchi; Shigeaki Muto; Chikako Hirashima; Shigeki Matsubara; Mitsuaki Suzuki
Journal:  CEN Case Rep       Date:  2013-08-23

7.  Measurement of sVEGF R1 and PlGF in serum: comparing prototype assays from Beckman Coulter, Inc. to R&D Systems microplate assays.

Authors:  Donald Wothe; Emanuel Gaziano; Shiraz Sunderji; Roberto Romero; Juan Pedro Kusanovic; Linda Rogers; Cheryl Hodges-Savola; Sean Roberts; James Wassenberg
Journal:  Hypertens Pregnancy       Date:  2010-05-19       Impact factor: 2.108

8.  Polymorphisms in Inflammatory Mediator Genes and Risk of Preeclampsia in Taiyuan, China.

Authors:  Weiwei Wu; Hailan Yang; Yongliang Feng; Ping Zhang; Shuzhen Li; Xin Wang; Tingting Peng; Fang Wang; Bingjie Xie; Pengge Guo; Mei Li; Ying Wang; Nan Zhao; Suping Wang; Yawei Zhang
Journal:  Reprod Sci       Date:  2016-08-04       Impact factor: 3.060

9.  Polymorphisms in complement genes and risk of preeclampsia in Taiyuan, China.

Authors:  Weiwei Wu; Hailan Yang; Yongliang Feng; Ping Zhang; Shuzhen Li; Xin Wang; Tingting Peng; Fang Wang; Bingjie Xie; Pengge Guo; Mei Li; Ying Wang; Nan Zhao; Dennis Wang; Suping Wang; Yawei Zhang
Journal:  Inflamm Res       Date:  2016-07-12       Impact factor: 4.575

10.  A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia.

Authors:  Juan Pedro Kusanovic; Roberto Romero; Tinnakorn Chaiworapongsa; Offer Erez; Pooja Mittal; Edi Vaisbuch; Shali Mazaki-Tovi; Francesca Gotsch; Samuel S Edwin; Ricardo Gomez; Lami Yeo; Agustin Conde-Agudelo; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2009-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.